OBJECTIVE: To quantify the cost-savings that could be realized by switching patients from two separate agents, ACE inhibitor/ARB and thiazide diuretic, to a fixed dose combination product. METHODS: CompuScript and Longitudinal Rx (LRx) Insights data from IMS Health Canada for Oct 2006-Sept 2007 was used. From the LRx data, the proportion of patients taking both ACE inhibitors/ARBs and thiazide diuretics as two separate products was calculated to determine how many would qualify for a combination product. From the CompuScript data, the total number of prescriptions for ACE inhibitors and ARBs and the actual average dollar value per prescription for thiazide diuretics, ACE inhibitors, ARBs, and ACE inhibitor/ARB with thiazide diuretic combination products was used to determine the potential cost savings of switching from two separate drugs to a combination product. As a sensitivity analysis, the proportion of patients receiving two separate products who could be switched to a combination product was varied from 60-100%. This analysis was done for Alberta and Canada. RESULTS: The conversion of ACE inhibitor/ARB and thiazide diuretic as two separate agents to a combination product could potentially result in a yearly cost-savings of $27 to $45 million for Canada ($1.1 to $1.9 million for Alberta), based on 60-100% conversion to a combination product. CONCLUSIONS: The present analysis has shown that a simple intervention of converting patients receiving separate ACE inhibitor/ARB and thiazide diuretic prescriptions to a single combination product prescription will produce substantial cost-savings for the health care system and simplify the medication regimen for patients.
OBJECTIVE: To quantify the cost-savings that could be realized by switching patients from two separate agents, ACE inhibitor/ARB and thiazide diuretic, to a fixed dose combination product. METHODS: CompuScript and Longitudinal Rx (LRx) Insights data from IMS Health Canada for Oct 2006-Sept 2007 was used. From the LRx data, the proportion of patients taking both ACE inhibitors/ARBs and thiazide diuretics as two separate products was calculated to determine how many would qualify for a combination product. From the CompuScript data, the total number of prescriptions for ACE inhibitors and ARBs and the actual average dollar value per prescription for thiazide diuretics, ACE inhibitors, ARBs, and ACE inhibitor/ARB with thiazide diuretic combination products was used to determine the potential cost savings of switching from two separate drugs to a combination product. As a sensitivity analysis, the proportion of patients receiving two separate products who could be switched to a combination product was varied from 60-100%. This analysis was done for Alberta and Canada. RESULTS: The conversion of ACE inhibitor/ARB and thiazide diuretic as two separate agents to a combination product could potentially result in a yearly cost-savings of $27 to $45 million for Canada ($1.1 to $1.9 million for Alberta), based on 60-100% conversion to a combination product. CONCLUSIONS: The present analysis has shown that a simple intervention of converting patients receiving separate ACE inhibitor/ARB and thiazide diuretic prescriptions to a single combination product prescription will produce substantial cost-savings for the health care system and simplify the medication regimen for patients.
Authors: Jason R Guertin; Cynthia A Jackevicius; Jafna L Cox; Karin Humphries; Louise Pilote; Derek Y So; Jack V Tu; Harindra Wijeysundera; Stéphane Rinfret Journal: CMAJ Date: 2011-01-24 Impact factor: 8.262
Authors: M Belén Ferro-Rey; Alex Roca-Cusachs; Antoni Sicras-Mainar; Carlos Alvarez-Martín; Marina de Salas-Cansado Journal: Aten Primaria Date: 2011-01-08 Impact factor: 1.137
Authors: Abdul Salam; Mark D Huffman; Raju Kanukula; Esam Hari Prasad; Abhishek Sharma; David J Heller; Rajesh Vedanthan; Anubha Agarwal; Anthony Rodgers; Marc G Jaffe; Thomas R Frieden; Sandeep P Kishore Journal: J Clin Hypertens (Greenwich) Date: 2020-08-20 Impact factor: 3.738